First human trial of artificial bypass graft begins

NCT ID NCT04545112

ENROLLING_BY_INVITATION Disease control Sponsor: Xeltis Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This early study tests a new synthetic blood vessel (XABG) for coronary artery bypass surgery in 20 people with multi-vessel heart disease. The graft is designed to work like a natural artery. Researchers are checking if it stays open and is safe in the first 30 days. This is a first step to see if the idea is feasible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: synthetic coronary artery bypass graft (XABG)
What this could lead to: If successful, this could provide a new option for bypass surgery, especially for patients who lack healthy veins for grafting.
What could go wrong: This is a very early, small study with only 20 participants. The graft may not stay open or could cause complications. Much more testing is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTI VESSEL CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTI VESSEL CORONARY ARTERY DISEASE

Contacts and locations

Locations

John Paul II Hospital Krakow

Krąków, Poland
Medicover Hospital

Warsaw, Poland
UZ Leuven

Leuven, Belgium
Vilnius University Hospital Santaros Klinikos

Vilnius, Lithuania

More trials for these conditions

Other studies related to the condition(s) this trial covers.